Isomorphic Labs in talks for about $5 billion in AI drug discovery funding
Alphabet-owned Isomorphic Labs is in talks to raise roughly five billion dollars to support artificial intelligence for drug discovery, Bloomberg Technology reports, citing people familiar with the matter. That scale would rank among the largest capital commitments to an AI-native discovery platform, sitting alongside a wider funding picture that includes reported cuts to OpenAI's fundraising target, syndication talks around a roughly forty-billion-dollar SpaceX chip financing package, and slower Chinese robotics fundraising in October. President Max Jaderberg has told Bloomberg that AI could eventually design all medicines, a vision the excerpts treat as forward-looking rather than clinically proven. The reporting describes negotiations, not a closed round with disclosed terms, investors, or use-of-proceeds detail, so the figure is best read as a signal of late-stage investor interest in long-horizon AI-bio platforms rather than evidence that specific drug programs have succeeded.
Isomorphic Labs in talks for about $5 billion in AI drug discovery funding
Alphabet Inc.’s Isomorphic Labs is in talks to raise roughly $5 billion in new funds to support its efforts to use artificial intelligence for drug discovery, according to people familiar with the matter. The piece describes funding talks rather than a completed round with disclosed terms.
Key takeaway
Treat the roughly five-billion-dollar figure as attributed talk-stage capital appetite for AI drug discovery, not proof of a finished round or validated pipeline outcomes.
What happened
Bloomberg Technology reports that Alphabet Inc.'s Isomorphic Labs is in talks to raise roughly $5 billion in new funds to support its efforts to use artificial intelligence for drug discovery, according to people familiar with the matter.
The owned-news framing states the piece describes funding talks rather than a completed round with disclosed terms, so no close date, investor roster, or valuation appears in the available excerpts.
Evidence
Isomorphic Labs is in talks to raise roughly $5 billion for AI drug discovery
Bloomberg Technology · attributed
Alphabet Inc.'s Isomorphic Labs is in talks to raise roughly $5 billion in new funds to support its efforts to use artificial intelligence for drug discovery, according to people familiar with the matter.
The reporting covers talks, not a completed financing with terms
Bloomberg Technology · attributed
The piece describes funding talks rather than a completed round with disclosed terms.
Isomorphic's president framed AI as eventually designing all medicines
Bloomberg Technology · attributed
Isomorphic Labs president Max Jaderberg thinks that artificial intelligence will be used to develop all medicines in the future — the only question is how quickly that future will arrive.
Why it matters
If the talks close at the reported size, builders and operators in AI-bio would face evidence that investors will underwrite capital-intensive discovery platforms, not only narrow software tools, amid mixed sector funding signals elsewhere in the packet.
Limits and uncertainties
The excerpt establishes only that talks are underway and attributes the figure to unnamed sources; it does not confirm the round's close, terms, investors, or how proceeds would be deployed.
Executive predictions that AI will design all drugs are opinion in the excerpts, not reports of completed technical or clinical milestones.
Practical implications
AI drug-discovery teams should plan runway and milestones assuming capital may stay talk-stage until terms and close are publicly confirmed.
Benchmark fundraising narratives against attributed reporting rather than headline round sizes when investors or partners ask for proof of progress.
What to watch
Public confirmation of whether Isomorphic Labs closes the reported round and any disclosed valuation, lead investors, or deployment plans.
Follow-on Bloomberg or primary disclosures tying the funding story to specific discovery programs or partnership milestones beyond executive interviews.
